A further study comparing FET PET with APTw CEST and perfusion (cerebral blood volume, CBV, from a dynamic susceptibility contrast acquisition) in 46 patients (31 IDH-wild-type and 12 IDH-mutant) observed both in IDH-wild-type glioblastomas and IDH-mutant lower grade gliomas relevant overlap between tumour areas defined by different imaging modalities, strongest not only for APTw and FET in contrast-enhancing parts of glioblastomas, but also in the FLAIR-hyperintense region of lower grade gliomas. The gene discussed is IDH2; the disease is glioblastoma.